Multifactorial diseases, where numerous pathologies and cellular networks are involved, require safe, multifunctional treatments.
The scientific teams at Axcella are leaders in elucidating and modeling amino acid biology and are leveraging their proprietary insights to develop a new treatment modality, called DAAC™ candidates. DAAC candidates are intended to elicit a powerful multifunctional effect through the cell which integrates the multiple cellular functions of amino acids. Each DAAC candidate is a rationally designed amino acid combination that harnesses this diverse activity and is intended to yield emergent synergies against dysregulated pathways in complex diseases with high unmet needs. Our robust pipeline is initially focused on programs in liver, muscle, CNS and other indications.
Amino acid biology impacts multiple cellular network systems implicated in disease including:
- Competitive transport
- Immune response and inflammation
- Mitochondrial activation and TCA cycle
The potential benefits of DAAC candidates include:
- Multifunctionality - simultaneously targeting multiple networks of dysregulated pathways
- Potential to treat a broad range of complex diseases
- Preliminary tolerability information, allowing for human data* to be integrated with preclinical development and inform candidate optimization.
- Rationally designed with the Axcellerator™ platform in a highly capital efficient manner
- Potentially differentiated tolerability relative to traditional polypharmacy
- Opportunity to be used as stand-alone or as a foundational combination agent in multi-drug therapeutic regimens
- Easily manufactured with competitive COGS
*Studies conducted under food and dietary supplement guidelines